|
1
|
Singal A, Kanwal F and Llovet J: Global
trends in hepatocellular carcinoma epidemiology: Implications for
screening, prevention and therapy. Nat Rev Clin Oncol. 20:864–884.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baecker A, Liu X, La Vecchia C and Zhang
ZF: Worldwide incidence of hepatocellular carcinoma cases
attributable to major risk factors. Eur J Cancer Prev. 27:205–212.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Konyn P, Ahmed A and Kim D: Current
epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol
Hepatol. 15:1295–1307. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao ZW, Cheng BQ, Zhou T and Gao YJ:
Management of hepatocellular carcinoma patients with portal vein
tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis
Int. 21:134–144. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tella SH, Kommalapati A and Mahipal A:
Systemic therapy for advanced hepatocellular carcinoma: Targeted
therapies. Chin Clin Oncol. 10:102021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan Y, Xue H and Zheng H: Systemic therapy
for hepatocellular carcinoma: Current updates and outlook. J
Hepatocell Carcinoma. 9:233–263. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lau WY, Wang K, Zhang XP, Li LQ, Wen TF,
Chen MS, Jia WD, Xu L, Shi J, Guo WX, et al: A new staging system
for hepatocellular carcinoma associated with portal vein tumor
thrombus. Hepatobiliary Surg Nutr. 10:782–795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung GE, Lee JH, Kim HY, Hwang SY, Kim
JS, Chung JW, Yoon JH, Lee HS and Kim YJ: Transarterial
chemoembolization can be safely performed in patients with
hepatocellular carcinoma invading the main portal vein and may
improve the overall survival. Radiology. 258:627–634. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YF, Guo RP, Zou RH, Shen JX, Wei W,
Li SH, OuYang HY, Zhu HB, Xu L, Lao XM and Shi M: Efficacy and
safety of preoperative chemoembolization for resectable
hepatocellular carcinoma with portal vein invasion: A prospective
comparative study. Eur Radiol. 26:2078–2088. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao XH, Yuan H, Xia WL, Zhang LL, Li Z,
Cao GS, Li HL, Fan WJ, Li HL, Guo CY, et al: Prospective study of
TACE combined with sorafenib vs TACE combined with 125I
seed implantation in the treatment of hepatocellular carcinoma with
portal vein tumor thrombus and arterioportal fistulas. Front Oncol.
12:9774622022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sidaway P: FOLFOX-HAIC active in large
HCC. Nat Rev Clin Oncol. 19:52022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsu SJ, Xu X, Chen MP, Zhao ZY, Wang Y,
Yin X, Zhang L, Ge NL, Chen Y, Wang YH, et al: Hepatic arterial
infusion chemotherapy with modified FOLFOX as an alternative
treatment option in advanced hepatocellular carcinoma patients with
failed or unsuitability for transarterial chemoembolization. Acad
Radiol. 28 (Suppl 1):S157–S166. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W,
Yuan Y, Zhang Y, Wang C, Qiu Z, et al: Conversion to resectability
using transarterial chemoembolization combined with hepatic
arterial infusion chemotherapy for initially unresectable
hepatocellular carcinoma. Ann Surg Open. 2:e0572021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
European Association for the Study of the
Liver, . EASL-ILCA clinical practice guidelines on the management
of intrahepatic cholangiocarcinoma. J Hepatol. 79:181–208. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 Practice
guidance by the american association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff
DC, Davidson JC, Qi X, Cheng SQ and Teng GJ: Management of patients
with hepatocellular carcinoma and portal vein tumour thrombosis:
Comparing east and west. Lancet Gastroenterol Hepatol. 4:721–730.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Zou R, Zheng Y, Qiu J, Shen J,
Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, et al: Lipiodol deposition
in portal vein tumour thrombus predicts treatment outcome in HCC
patients after transarterial chemoembolisation. Eur Radiol.
29:5752–5762. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
National Cancer Institute, . Cancer
Therapy Evaluation Program. Common Toxicity Criteria for Adverse
Events. Version 5.0, 2017. Available from:. http://ctep.cancer.govMay 10–2021
|
|
22
|
Park JW, Kim YJ, Kim DY, Bae SH, Paik SW,
Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, et al: Sorafenib with or
without concurrent transarterial chemoembolization in patients with
advanced hepatocellular carcinoma: The phase III STAH trial. J
Hepatol. 70:684–691. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He MK, Liang RB, Zhao Y, Xu YJ, Chen HW,
Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al: Lenvatinib,
toripalimab, plus hepatic arterial infusion chemotherapy versus
lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv
Med Oncol. Mar 25–2021.(Epub ahead of print). View Article : Google Scholar
|
|
24
|
Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi
Y, Lin Z, Zheng Y, Chen M, Lau WY, et al: TACE-HAIC combined with
targeted therapy and immunotherapy versus TACE alone for
hepatocellular carcinoma with portal vein tumour thrombus: A
propensity score matching study. Int J Surg. 109:1222–1230. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu
SX, Zhang X, Wang XD, Cao G, Chen H, et al: Combination therapy of
chemoembolization and hepatic arterial infusion chemotherapy in
hepatocellular carcinoma with portal vein tumor thrombosis compared
with chemoembolization alone: A propensity score-matched analysis.
Biomed Res Int. 2021:66703672021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheu JWSC and Wong CCL: Mechanistic
rationales guiding combination hepatocellular carcinoma therapies
involving immune checkpoint inhibitors. Hepatology. 74:2264–2276.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cai M, Huang W, Huang J, Shi W, Guo Y,
Liang L, Zhou J, Lin L, Cao B, Chen Y, et al: Transarterial
chemoembolization combined with lenvatinib plus PD-1 inhibitor for
advanced hepatocellular carcinoma: A retrospective cohort study.
Front Immunol. 13:8483872022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Z, Jiao T, Li J, Hu B, Zhang W, Wang
Z, Wan T, Wang Y and Lu S: Efficacy of treatment based on TKIs in
combination with PD-1 inhibitors for unresectable recurrent
hepatocellular carcinoma. World J Surg Oncol. 21:532023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu XD, Huang C, Shen YH, Ji Y, Ge NL, Qu
XD, Chen L, Shi WK, Li ML, Zhu JJ, et al: Downstaging and resection
of initially unresectable hepatocellular carcinoma with tyrosine
kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer.
10:320–329. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pinato D, Guerra N, Fessas P, Murphy R,
Mineo T, Mauri FA, Mukherjee SK, Thursz M, Wong CN, Sharma R and
Rimassa L: Immune-based therapies for hepatocellular carcinoma.
Oncogene. 39:3620–3637. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He X and Xu C: Immune checkpoint signaling
and cancer immunotherapy. Cell Res. 30:660–669. 2020. View Article : Google Scholar : PubMed/NCBI
|
